Hualan Biological Vaccine Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Cash & Equivalents	854.14	623.04	640.98	600.04	131.56	412.39
Short-Term Investments	687.18	1,145	373.46	130	-	-
Trading Asset Securities	1,534	1,458	1,599	1,419	825.82	452.86
Cash & Short-Term Investments	3,076	3,227	2,613	2,149	957.39	865.25
Cash Growth	21.14%	23.48%	21.57%	124.50%	10.65%	72.84%
Accounts Receivable	1,348	1,438	1,990	1,796	1,439	1,530
Other Receivables	0.57	0.41	1.31	0.41	2.15	2.18
Receivables	1,349	1,438	2,412	1,856	1,441	1,532
Inventory	269.42	208.84	173.47	167.16	107.41	45.27
Other Current Assets	86	103.13	28.18	20.22	23.31	22.86
Total Current Assets	4,780	4,977	5,227	4,193	2,529	2,465
Property, Plant & Equipment	971.5	1,071	1,176	1,287	1,351	810.97
Long-Term Investments	-	1,204	1,296	1,310	356.3	-
Other Intangible Assets	20.29	20.88	20.13	20.78	21.43	22.08
Long-Term Deferred Tax Assets	204.76	212.73	217.97	208.56	182.9	170.41
Long-Term Deferred Charges	27.87	27.79	27.94	28.69	33.36	19.58
Other Long-Term Assets	1,175	11.05	30.61	27.98	48.93	159.61
Total Assets	7,179	7,523	7,995	7,076	4,523	3,648
Accounts Payable	73.37	81.78	116.76	125.67	185.5	105.46
Accrued Expenses	-	903.53	1,155	1,050	929.48	956.07
Short-Term Debt	-	300.18	300.18	300.18	500.44	200
Current Portion of Leases	-	-	-	-	1.03	-
Current Income Taxes Payable	6.26	-	50.81	9.24	15.99	154.44
Current Unearned Revenue	4.59	8.74	2.67	2.68	1.54	1.89
Other Current Liabilities	1,380	169.9	60.63	49.13	38.19	36.74
Total Current Liabilities	1,464	1,464	1,686	1,537	1,672	1,455
Long-Term Leases	-	-	-	-	0.81	-
Long-Term Unearned Revenue	24.01	27.19	31.42	35.66	39.89	6
Long-Term Deferred Tax Liabilities	16.16	18.8	15.22	6.41	2.5	0.28
Total Liabilities	1,505	1,510	1,732	1,579	1,715	1,461
Common Stock	601.03	601.03	600.02	400.01	360	360
Additional Paid-In Capital	2,931	2,926	2,915	3,089	879.79	879.79
Retained Earnings	2,249	2,593	2,748	2,008	1,568	947.34
Treasury Stock	-106.79	-106.79	-	-	-	-
Shareholders' Equity	5,675	6,013	6,263	5,497	2,808	2,187
Total Liabilities & Equity	7,179	7,523	7,995	7,076	4,523	3,648
Total Debt	-	300.18	300.18	300.18	502.27	200
Net Cash (Debt)	3,076	2,926	2,313	1,849	455.12	665.25
Net Cash Growth	37.38%	26.53%	25.07%	306.31%	-31.59%	32.89%
Net Cash Per Share	5.17	4.89	3.84	3.13	0.84	1.23
Filing Date Shares Outstanding	595	595	600.02	600.02	600.02	600.02
Total Common Shares Outstanding	595	595	600.02	600.02	540	540
Working Capital	3,316	3,512	3,541	2,656	857.07	1,011
Book Value Per Share	9.54	10.11	10.44	9.16	5.20	4.05
Tangible Book Value	5,655	5,992	6,243	5,476	2,787	2,165
Tangible Book Value Per Share	9.50	10.07	10.40	9.13	5.16	4.01
Buildings	-	376.55	376.55	376.19	375.5	169.91
Machinery	-	1,496	1,472	1,450	1,388	688.28
Construction In Progress	-	6.72	3.23	3.26	-	315.55

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.